Navigation Links
Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Date:12/31/2008

/p>

Please discuss this with your doctor, before starting treatment, especially if:

  • you already know you have an increased risk of thrombosis
  • you, or anyone in your immediate family, have ever had a thrombosis
  • you are severely overweight.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine. You should not use PUREGON if you are already pregnant, or suspect that you might be pregnant, or if you are breast-feeding.

After treatment with gonadotropin preparations, there is an increased risk of having multiple pregnancies. Multiple pregnancies carry an increased health risk for both the mother and her babies around the time of birth. Furthermore, multiple pregnancies and characteristics of the patients undergoing fertility treatment (e.g. age of the female, sperm characteristics) may be associated with an increased risk of congenital abnormalities. There is a slightly increased risk of extra-uterine pregnancy in women with damaged fallopian tubes.

In women undergoing fertility treatment there may be a slightly higher risk of miscarriage.

Possible side effects

Like all medicines, PUREGON can cause side effects, although not everybody gets them.

Minor side effects include bruising, pain, redness, swelling and itching at the site of the injection. Occasionally, more widespread reactions like rash have been observed.

A complication with FSH treatment is unwanted overstimulation of the ovaries. This condition can become very serious, but the risk can be reduced by careful monitoring of follicle development during treatment. The first symptoms of ovarian overstimulation may be noticed as pain in the abdomen, feeling sick or diarrhoea. In more severe cases symptoms may include enlargement of the ovaries, accumulation o
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., ORLANDO, Fla., Dec. 4 , ,What:...a,s largest Medicare, health benefit... ( http://humanagames.com ), a senior-friendly da... Guidance Center on Tues., Dec. 8 a... free and open to the public, will feature...
(Date:12/4/2009)...ION, N.J., Dec. 4 PLUS Diagnostic...lty anatomic pathology services with the launch of...service completes the company,s expansion from a r...pathology company offering diagnostic services acr...terology, urology and now hematology/oncology. ,...
(Date:12/4/2009)...EATTLE, Dec. 4 The National Cancer...ear contract to Fred Hutchinson Cancer Research Ce...ancer Information Service Contact Center. ,, Th...enter - nearly tripling the size of its current CI...y operational, which is scheduled for March 15, 20...
(Date:12/4/2009)... Lexi-Comp,s multi-language patient educa...to establish standards for language access in heal...udson, OH (PRWEB) December 5, 2009 -- Lexi-Comp, I... solutions, and patient education materials for he...of effective communication between the health care...
(Date:12/4/2009)...ren less likely to get herpes zoster virus, study ...) -- Children who are vaccinated against chicken p...gles, new findings suggest. , U.S. researchers ...n southern California who were vaccinated with the...2008. , Over an average of 2.5 years after rece...
Breaking Medicine News(10 mins):Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
...oimmune disease is a condition in which the immune...gressively as it would attack a foreign pathogen. ... autoimmune disease, and is one of the most common...ttack the central nervous system. It has long been...
...lty from the University of Michigan , University... key collaborators in study , , DETROIT, April ...ecently discovered a chemical that plays a major r...rofessor of psychiatry in the School of Medicine a...
...-Week Data Supports Long-term Use of Vectical(TM) ... Patients - , , FORT WORTH, Texas, April 30 Gald...om a newly published clinical trial in this month,...o-moderate chronic plaque psoriasis. Of those pati...
...ches Women of Hope is Beautiful Campaign to Inspir...confidence, control, community, caring -- ask any...ly find meaning in these words. They are also inte...ent. The program, which is celebrating its 20th an...
...st radiosurgery solutions from Elekta discussed ...t the 2009 American Association of Neurological Su...iego Convention Center, Elekta customers and perso...nd oncologists today. , , Local Control of Brain...
...INTON, Mass., April 30 Alseres Pharmaceuticals, I... that on April 24, 2009 it entered into an Amendme...Therapeutic, Inc. (BioAxone), pursuant to which th...amended. The Amendment replaces all of the pre-co...
Other Medicine News:Health News:Gray matter under attack in multiple sclerosis 2Health News:Gray matter under attack in multiple sclerosis 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 2Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 4Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 2Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 3Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 4Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 2Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 3Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 4Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 2Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 2Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 4
(Date:12/3/2009)... Ted Karkus, Chairman an... www.quigleyco.com announced today that the Comp...ies to develop prescription pharmaceutical and OTC... interests to focus primarily on the OTC/Personal ...mited to its Cold-EEZE® and Kids-EEZE® b...
(Date:12/3/2009)...rk and SAN DIEGO, California, December 3 /PRNewswi...miR-122, a microRNA Important for,Hepatitis C Vira...titis C,Virus in the Bloodstream in Chimpanzees Ch..., - SPC3649 Demonstrates Efficacy With No Evi...vents in the Treated Animals - Signaling a Potenti...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Lure of Bottled Water May Not Be Health Driven 49525 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 2Make Nursing Homes More Like Home 3A Medicare 49521 1Make Nursing Homes More Like Home 3A Medicare 49521 2
...ive Insulin-Based Therapies, Market,Growth Will be...om Decision Resource...ne of the,world,s leading research and advisory fi...s that the most significant driver of growth in th...standard of care away from,regular human insulins ...
...09, SEATTLE, Aug. 12 Cell Therapeutics, Inc.,s,(...cine (SM) announced today,that planned enrollment ...rch and Treatment of Cancer (EORTC) randomized pha...ith newly diagnosed advanced or metastatic,soft ti...he primary,endpoint of the trial is progression-fr...
Other Medicine Technology:Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: